Biomm S.A. (BVMF:BIOM3)
Brazil · Delayed Price · Currency is BRL 6.61
-0.79 (-10.68%)
Nov 7, 2025, 6:07 PM GMT-3
Biomm Company Description
Biomm S.A. operates as a biotechnology company in Brazil.
The company offers AFREZZA, a human insulin inhalation powder; GHEMAXAN, an enoxaparina sodica; GLARGILIN, a glargine insulin; WOSULIN R, a human insulin; WOSULIN N, an isophane insulin; HERZUMA, a trastuzumab; and CANETA LIFEPEN G PARA APLICACAO DE INSULINA.
Biomm S.A. was founded in 2001 and is headquartered in Nova Lima, Brazil.
Biomm S.A.
| Country | Brazil |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 130 |
| CEO | Heraldo Marchezini |
Contact Details
Address: 705 – Lagoa dos Ingleses Nova Lima, 34018-000 Brazil | |
| Phone | 55 31 3299 1000 |
| Website | biomm.com |
Stock Details
| Ticker Symbol | BIOM3 |
| Exchange | Brazil Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | BRL |
| ISIN Number | BRBIOMACNOR2 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Heraldo Carvalho Marchezini | Chief Executive Officer and Member of the Executive Board |
| Marcelo Sáfadi Alvares | Chief Financial Officer and IR |
| Francisco Carlos Marques de Freitas | Director of Technology and Member of the Executive Board |
| Francisco Rafael Costa Jr. | Commercial Director and Member of Executive Board |
| Luciano da Silva Machado | Operations Director and Member of Executive Board |
| Nayara Rodrigues de Souza Cruz | Accountant |